NERVMinerva Neurosciences, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $3.49 · now $3.49 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, NERV has typically landed between $2.26 and $5.69 — a range of −35.2% to +62.9% from the issuance price $3.49.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

3,043 overlapping 1 month windows · 2014-07-012026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($3.49) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where NERV has typically landed a month from the 2026-09-16 close of $3.49 — the range is history, not a prediction.

$2.26worst · -35.2%$5.69best · +62.9%
  • now $3.49 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $3.39 (-2.7%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $2.87$3.91
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $2.26$5.69
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 3,043 windows spanning 2014-07-01 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-02-06−79.5%−79.5%+0.0%
2024-02-05−75.9%−76.1%+15.6%
2020-05-26−75.7%−76.9%+0.0%
3 best
2022-07-28+395.1%−3.0%+395.1%
2022-07-27+360.9%+0.0%+360.9%
2022-07-29+320.9%−3.7%+391.4%

3,043 overlapping windows · 2014-07-012026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~13 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
67%
+8.2%
n=12
Feb
25%
−6.2%
n=12
Mar
33%
−0.6%
n=12
Apr
50%
+5.2%
n=12
May
58%
+20.5%
n=12
Jun
67%
+1.6%
n=12
Jul
33%
−5.6%
n=12
Aug
54%
+29.3%
n=13
Sep
31%
−2.1%
n=13
Oct
25%
−12.3%
n=12
Nov
50%
+7.8%
n=12
Dec
33%
−8.0%
n=12

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$8$2↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

26 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-08-03Kaul InderjitdirectorAward / grant12,14712,147Form 4
2026-06-03Ahlholm Frederick WofficerAward / grant680,000680,000Form 4
2026-06-03HASLER HANS PETERdirectorAward / grant50,00050,000Form 4
2026-06-03Kaul InderjitdirectorAward / grant50,00050,000Form 4
2026-06-03Kupfer DaviddirectorAward / grant50,00050,000Form 4
2026-06-03Laghrissi-Thode FouziadirectorAward / grant50,00050,000Form 4
2026-06-03Luthringer RemydirectorAward / grant1,690,7001,690,700Form 4
2026-06-03VAN HEEK G JANdirectorAward / grant50,00050,000Form 4
2026-04-21O'Connor James JosephofficerAward / grant350,800350,800Form 4
2026-03-31Kaul InderjitdirectorAward / grant12,16912,169Form 4
2025-12-22HASLER HANS PETERdirectorAward / grant50,00050,000Form 4
2025-12-22VAN HEEK G JANdirectorAward / grant50,00050,000Form 4
2025-12-22Ahlholm Frederick WofficerAward / grant500,000500,000Form 4
2025-12-22Race GeoffofficerAward / grant1,500,0001,500,000Form 4
2025-12-22Luthringer RemydirectorAward / grant2,250,0002,250,000Form 4
2025-12-22Laghrissi-Thode FouziadirectorAward / grant50,00050,000Form 4
2025-12-22Kaul InderjitdirectorAward / grant364,504364,504Form 4
2025-12-22Kupfer DaviddirectorAward / grant50,00050,000Form 4
2025-11-14Kaul InderjitdirectorAward / grant9,5009,500Form 4
2024-12-05Ahlholm Frederick WofficerAward / grant47,50047,500Form 4
2024-12-05HASLER HANS PETERdirectorAward / grant12,50012,500Form 4
2024-12-05Kupfer DaviddirectorAward / grant12,50012,500Form 4
2024-12-05Laghrissi-Thode FouziadirectorAward / grant12,50012,500Form 4
2024-12-05Luthringer RemydirectorAward / grant105,000105,000Form 4
2024-12-05Race GeoffofficerAward / grant95,00095,000Form 4
2024-12-05VAN HEEK G JANdirectorAward / grant12,50012,500Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.